ERBB2 and breast cancer: Previous testing of BMS-754807 in a panel of 30 BC cell lines revealed that basal-like/TNBC cell lines were more sensitive to BMS-754807, while luminal/HER2 overexpressing cell lines showed greater resistance [48].